N@N

Monogram Announces Presentations to be made at the CTRC-AACR San Antonio Breast Cancer Symposium

^{Published on 2008-12-08 07:35:12 - Market Wire}
 

SOUTH SAN FRANCISCO, Calif.--([ BUSINESS WIRE ])--Monogram Biosciences, Inc. (Nasdaq:MGRM) today announced that several presentations will be made at the CTRC-AACR San Antonio Breast Cancer Symposium, to be held at the Henry B. Gonzalez Convention Center, December 10-14 in San Antonio, Texas. The presentations will discuss Monogram's HERmark™ Breast Cancer Assay and the VeraTag™ technology platform. Following are the embargoed presentations:

Poster Presentation:Quantitative HER2 homodimer levels correlate with time to first recurrence in HER2-positive breast cancer patients who did not receive trastuzumab in the adjuvant setting.

Presented by Michael Bates, MD

Poster # 1074, poster session 1, Exhibit Hall B; Thursday December 11, 5:30-7:30pm

Poster Presentation: Quantitative measurements of HER2 expression and HER2 homodimer using a novel proximity-based assay:comparison with HER2 status by immunohistochemistry and chromogenic in situ hybridization in the FinHer study.

Presented by Heikki Joensuu, MD

Poster# 2071, session 2; Exhibit Hall B; Friday December 12, 7:00-9:00 am

Oral Presentation:HER2 Protein expression and homodimer levels predict response to trastuzumab in centrally tested FISH-positive metastatic breast cancer patients.

Presented by Allan Lipton, MD

Oral General Session 3; Exhibit Hall D; Friday December 12, 9:30-11:15 am

Poster Presentation: Proximity-based assays for the detection of activated HER3, HER2/HER3 heterodimers and HER3/PI3K complexes in formalin-fixed, paraffin-embedded cell line controls and tumors.

Presented by Ali Mukherjee, PhD

Poster: #4040; Exhibit Hall B; Saturday December 13, 7:00-9:00 am

About Monogram

Monogram is advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biopharmaceutical companies to develop new and improved anti-viral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at [ www.monogrambio.com ].

Forward Looking Statements

Certain statements in this press release are forward-looking, including statements regarding the capabilities of our HERmark and VeraTag assays, the potential for enhancements to our HERmark assay, the development of additional assays based on the VeraTag platform, the results and timing of clinical studies on our products and the presentation or publication of data from such studies. These forward-looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to: risks and uncertainties relating to the performance and acceptance of our products; the risk that our VeraTag assays, including HERmark, may not predict response to particular therapeutic agents; the risk that we may not be able to obtain additional cohorts of patient samples for additional VeraTag studies, the risk that our VeraTag technology may not accurately measure other proteins or protein complexes, our ability to successfully conduct clinical studies and the results obtained from those studies; whether larger confirmatory clinical studies will confirm the results of initial studies; our ability to establish reliable, high-volume operations at commercially reasonable costs; actual market acceptance of our products and adoption of our technological approach and products by pharmaceutical and biotechnology companies; our estimate of the size of our markets; our estimates of the levels of demand for our products; the impact of competition; whether payers will authorize reimbursement for our products and services and the amount of such reimbursement that may be allowed; whether the FDA or any other agency will decide to further regulate our products or services, including HERmark; whether the draft guidance on Multivariate Index Assays issued by the FDA will be subsequently determined to apply to our current or planned products; whether we will encounter problems or delays in automating our processes; the ultimate validity and enforceability of our patent applications and patents; the possible infringement of the intellectual property of others; whether licenses to third party technology will be available; whether we are able to build brand loyalty and expand revenues; restrictions on the conduct of our business imposed by the Pfizer, G.E. and other debt agreements; and whether we will be able to raise sufficient capital in the future, if required. For a discussion of other factors that may cause actual events to differ from those projected, please refer to our most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent filings with the Securities and Exchange Commission. We do not undertake, and specifically disclaim any obligation, to revise any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements.

VeraTag and HERmark are trademarks of Monogram Biosciences, Inc.